Candriam S.C.A. Neurocrine Biosciences Inc Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Candriam S.C.A. holds 483,241 shares of NBIX stock, worth $60.7 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

483,241

Previous 465,467 3.82%

Holding current value

$60.7 Million

Previous $64.1 Million 13.18%

% of portfolio

0.33%

Previous 0.39%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $2.04 Million - $2.72 Million	17,774 Added 3.82%	483,241 $55.6 Million
Q2 2024 Aug 05, 2024	BUY	$130.86 - $143.19 $19.6 Million - $21.4 Million	149,783 Added 47.45%	465,467 $64.1 Million
Q1 2024 May 03, 2024	SELL	$130.4 - $143.74 $7.07 Million - $7.79 Million	-54,215 Reduced 14.66%	315,684 $43.5 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $778,447 - $974,325	-7,339 Reduced 1.95%	369,899 $48.7 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $5.94 Million - $7.4 Million	-63,178 Reduced 14.35%	377,238 $42.4 Million
Q2 2023 Aug 08, 2023	BUY	$89.53 - $104.87 $2.08 Million - $2.44 Million	23,236 Added 5.57%	440,416 $41.5 Million
Q1 2023 May 12, 2023	BUY	$94.11 - $123.02 $13.9 Million - $18.2 Million	148,008 Added 54.99%	417,180 $42.2 Million
Q4 2022 Feb 13, 2023	SELL	$106.72 - $127.06 $246,416 - $293,381	-2,309 Reduced 0.85%	269,172 $32.1 Million
Q3 2022 Nov 10, 2022	SELL	$92.03 - $107.81 $5.47 Million - $6.41 Million	-59,448 Reduced 17.96%	271,481 $28.8 Million
Q2 2022 Aug 03, 2022	BUY	$75.79 - $100.07 $2.33 Million - $3.07 Million	30,722 Added 10.23%	330,929 $32.3 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $703,199 - $920,225	-9,706 Reduced 3.13%	300,207 $28.1 Million
Q4 2021 Feb 10, 2022	BUY	$79.65 - $106.22 $18.2 Million - $24.3 Million	228,400 Added 280.2%	309,913 $26.4 Million
Q3 2021 Nov 09, 2021	BUY	$86.18 - $99.03 $1,723 - $1,980	20 Added 0.02%	81,513 $7.82 Million
Q2 2021 Jul 20, 2021	SELL	$89.43 - $102.27 $7.24 Million - $8.28 Million	-80,976 Reduced 49.84%	81,493 $7.93 Million
Q4 2020 Jan 22, 2021	BUY	$86.91 - $108.33 $537,712 - $670,237	6,187 Added 3.96%	162,469 $16.6 Million
Q2 2020 Jul 23, 2020	SELL	$85.09 - $130.36 $2.59 Million - $3.97 Million	-30,484 Reduced 16.32%	156,282 $19.1 Million
Q4 2019 Jan 21, 2020	SELL	$86.8 - $118.57 $1.55 Million - $2.12 Million	-17,903 Reduced 8.75%	186,766 $20,000
Q3 2019 Oct 21, 2019	SELL	$83.82 - $101.5 $5.28 Million - $6.39 Million	-63,000 Reduced 23.54%	204,669 $18,000
Q2 2019 Aug 01, 2019	SELL	$72.24 - $91.27 $1.81 Million - $2.28 Million	-25,000 Reduced 8.54%	267,669 $22.5 Million
Q1 2019 May 02, 2019	BUY	$69.31 - $91.53 $4.48 Million - $5.91 Million	64,600 Added 28.32%	292,669 $25.8 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $5.33 Million - $9.7 Million	78,000 Added 51.98%	228,069 $16.3 Million
Q3 2018 Nov 07, 2018	BUY	$98.88 - $125.85 $6.92 Million - $8.81 Million	69,969 Added 87.35%	150,069 $18.5 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $1.14 Million - $1.6 Million	15,100 Added 23.23%	80,100 $7.87 Million
Q1 2018 May 09, 2018	SELL	$75.88 - $92.43 $2.66 Million - $3.24 Million	-35,000 Reduced 35.0%	65,000 $5.39 Million
Q4 2017 Feb 07, 2018	SELL	$58.53 - $77.59 $17.1 Million - $22.7 Million	-292,000 Reduced 74.49%	100,000 $7.76 Million
Q3 2017 Nov 03, 2017	BUY	$47.97 - $61.28 $18.8 Million - $24 Million	392,000	392,000 $24 Million

Others Institutions Holding NBIX

# of Institutions

629

Shares Held

94.2M

Call Options Held

692K

Put Options Held

406K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account